Nothing Special   »   [go: up one dir, main page]

MX2017006694A - Compuestos biciclicos fusionados para el tratamiento de enfermedades. - Google Patents

Compuestos biciclicos fusionados para el tratamiento de enfermedades.

Info

Publication number
MX2017006694A
MX2017006694A MX2017006694A MX2017006694A MX2017006694A MX 2017006694 A MX2017006694 A MX 2017006694A MX 2017006694 A MX2017006694 A MX 2017006694A MX 2017006694 A MX2017006694 A MX 2017006694A MX 2017006694 A MX2017006694 A MX 2017006694A
Authority
MX
Mexico
Prior art keywords
disease
treatment
fused bicyclic
bicyclic compounds
compounds
Prior art date
Application number
MX2017006694A
Other languages
English (en)
Other versions
MX370480B (es
Inventor
Mohan Raju
Anthony Pratt Benjamin
Original Assignee
Akarna Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akarna Therapeutics Ltd filed Critical Akarna Therapeutics Ltd
Publication of MX2017006694A publication Critical patent/MX2017006694A/es
Publication of MX370480B publication Critical patent/MX370480B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En la presente se describen compuestos bicíclicos fusionados, composiciones y método para uso para el tratamiento de enfermedades.
MX2017006694A 2014-11-21 2015-11-20 Compuestos bicíclicos fusionados para el tratamiento de enfermedades. MX370480B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462083031P 2014-11-21 2014-11-21
PCT/US2015/062017 WO2016081918A1 (en) 2014-11-21 2015-11-20 Fused bicyclic compounds for the treatment of disease

Publications (2)

Publication Number Publication Date
MX2017006694A true MX2017006694A (es) 2018-03-16
MX370480B MX370480B (es) 2019-12-16

Family

ID=56014622

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006694A MX370480B (es) 2014-11-21 2015-11-20 Compuestos bicíclicos fusionados para el tratamiento de enfermedades.

Country Status (18)

Country Link
US (4) US10233187B2 (es)
EP (1) EP3221321B1 (es)
JP (3) JP7224102B2 (es)
KR (1) KR20170117020A (es)
CN (2) CN107207513B (es)
AU (2) AU2015349687B2 (es)
CA (1) CA2968434A1 (es)
CL (1) CL2017001289A1 (es)
CO (1) CO2017005784A2 (es)
ES (1) ES2911293T3 (es)
HK (1) HK1244802A1 (es)
IL (1) IL252309B (es)
MX (1) MX370480B (es)
MY (1) MY192927A (es)
RU (1) RU2706007C2 (es)
SA (1) SA517381566B1 (es)
SG (2) SG11201703953WA (es)
WO (1) WO2016081918A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
BR112017002214B1 (pt) 2014-08-04 2023-03-07 Nuevolution A/S Composto de fórmula (i), e uso de um composto
MX370480B (es) * 2014-11-21 2019-12-16 Akarna Therapeutics Ltd Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
JP6843061B2 (ja) * 2015-03-26 2021-03-17 アカーナ・セラピューティクス・リミテッドAkarna Therapeutics, Ltd. 疾患治療のための縮合二環化合物
US20200397798A1 (en) * 2016-05-25 2020-12-24 Akarna Therapeutics, Ltd. Combination therapies with farnesoid x receptor (fxr) modulators
MX2018015443A (es) 2016-06-13 2019-04-11 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4).
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
KR20220119520A (ko) 2017-03-28 2022-08-29 길리애드 사이언시즈, 인코포레이티드 간 질환을 치료하기 위한 치료 조합물
AU2018275674A1 (en) * 2017-06-02 2020-01-16 Akarna Therapeutics, Ltd. Fused bicyclic compounds
PT3911647T (pt) 2019-01-15 2024-03-04 Gilead Sciences Inc Composto de isoxazole como agonista de fxr e composições farmacêuticas que o contenham
CN118388473A (zh) 2019-02-19 2024-07-26 吉利德科学公司 Fxr激动剂的固体形式
CN111825653A (zh) * 2019-04-19 2020-10-27 安道麦马克西姆有限公司 取代吡唑类化合物的制备及其作为邻氨基苯甲酰胺前体的用途
US20220265614A1 (en) 2019-07-23 2022-08-25 Novartis Ag Treatment comprising fxr agonists
WO2021014350A1 (en) 2019-07-23 2021-01-28 Novartis Ag Combination treatment of liver diseases using fxr agonists
KR20220054608A (ko) 2019-09-03 2022-05-03 노파르티스 아게 ActRII 수용체 길항제를 포함하는 간 질환 또는 장애 치료제
CN114401745A (zh) 2019-09-19 2022-04-26 诺华股份有限公司 包含fxr激动剂的治疗
WO2021064575A1 (en) 2019-09-30 2021-04-08 Novartis Ag Treatment comprising the use of fxr agonists
KR20220119424A (ko) 2019-12-20 2022-08-29 노파르티스 아게 인테그린 억제제를 사용한 간 질환의 조합 치료
JP2021098692A (ja) 2019-12-20 2021-07-01 ヌエヴォリューション・アクティーゼルスカブNuevolution A/S 核内受容体に対して活性の化合物
CA3174252A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
WO2021198956A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
TW202227405A (zh) * 2020-08-24 2022-07-16 以色列商安道麥馬克西姆有限公司 用於製備經取代的吡唑之方法
WO2022101853A1 (en) 2020-11-16 2022-05-19 Novartis Ag Method of determining liver fibrosis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
KR20060052867A (ko) * 2003-07-23 2006-05-19 엑셀리시스, 인코포레이티드 약제로서의 아제핀 유도체
EA200801812A1 (ru) * 2003-09-17 2009-06-30 Янссен Фармацевтика Н.В. Сопряженные гетероциклические соединения
US20090137554A1 (en) * 2007-10-22 2009-05-28 Wyeth 1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
US20090215748A1 (en) * 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
EP2334681A1 (en) * 2008-09-26 2011-06-22 Wyeth LLC 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors
US8252826B2 (en) * 2010-03-24 2012-08-28 Hoffmann-La Roche Inc. Cyclopentyl- and cycloheptylpyrazoles
MX370480B (es) * 2014-11-21 2019-12-16 Akarna Therapeutics Ltd Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
JP2019520335A (ja) * 2016-05-25 2019-07-18 アカーナ・セラピューティクス・リミテッドAkarna Therapeutics, Ltd. 疾患治療用の縮合二環式化合物

Also Published As

Publication number Publication date
MX370480B (es) 2019-12-16
AU2020250270B2 (en) 2022-08-25
ES2911293T3 (es) 2022-05-18
CL2017001289A1 (es) 2018-03-02
IL252309A0 (en) 2017-07-31
WO2016081918A1 (en) 2016-05-26
AU2015349687B2 (en) 2020-07-09
EP3221321A1 (en) 2017-09-27
US10233187B2 (en) 2019-03-19
CN107207513A (zh) 2017-09-26
US20230183247A1 (en) 2023-06-15
CN107207513B (zh) 2020-07-28
AU2020250270A1 (en) 2020-11-05
US20190308977A1 (en) 2019-10-10
SG11201703953WA (en) 2017-06-29
EP3221321A4 (en) 2018-04-25
BR112017010627A2 (pt) 2018-02-14
MY192927A (en) 2022-09-15
RU2017121588A (ru) 2018-12-24
JP7224102B2 (ja) 2023-02-17
JP2023011731A (ja) 2023-01-24
CO2017005784A2 (es) 2017-10-31
AU2015349687A1 (en) 2017-06-29
HK1244802A1 (zh) 2018-08-17
RU2706007C2 (ru) 2019-11-13
KR20170117020A (ko) 2017-10-20
JP2017535614A (ja) 2017-11-30
JP2021011482A (ja) 2021-02-04
EP3221321B1 (en) 2021-12-15
US20170355699A1 (en) 2017-12-14
RU2017121588A3 (es) 2019-05-21
IL252309B (en) 2021-01-31
CA2968434A1 (en) 2016-05-26
CN111662297A (zh) 2020-09-15
SG10202010386PA (en) 2020-11-27
US20210147426A1 (en) 2021-05-20
SA517381566B1 (ar) 2021-05-16

Similar Documents

Publication Publication Date Title
MY192927A (en) Fused bicyclic compounds for the treatment of disease
IL264049A (en) Compounds, preparations and methods for treating the disease
MX369623B (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
IL264156A (en) Compounds, preparations and methods for treating the disease
ZA201700737B (en) Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer
MX2023008686A (es) Polinucleotidos moduladores.
PH12016501763A1 (en) Multispecific antibodies
WO2016100985A3 (en) Chimeric antigen receptors and methods of use thereof
MY184870A (en) Immunomodulators
MD20170032A2 (ro) Anticorpi anti-TIGIT
MY176855A (en) Anti-jagged1 antibodies and methods of use
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EP3169405A4 (en) Methods, compounds, and compositions for the treatment of musculoskeletal diseases
PH12017500602A1 (en) Methods for treating ocular conditions
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
HRP20181123T1 (hr) Spojevi 3,4-diamino-6-kloropirazin-2-karboksamida za liječenje bolesti posredovanih s enac

Legal Events

Date Code Title Description
FG Grant or registration